A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV)
10.3760/cma.j.issn.1671-0282.2020.03.003
- VernacularTitle: 洛匹那韦/利托那韦(LPV/r)联合恩曲他滨/丙酚替诺福韦（FTC/TAF）联合方案用于新型冠状病毒肺炎治疗的临床研究方案（TARCoV研究）
- Author:
Hua JIANG
1
;
Yu WANG
1
;
Kai WANG
1
;
Xingxiang YANG
2
;
Jiancheng ZHANG
1
;
Hongfei DENG
1
;
Lu WANG
1
;
Jun ZENG
1
Author Information
1. Institute for Emergency and Disaster Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China
2. Department of Infection, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China
- Publication Type:Journal Article
- Keywords:
Novel coronavirus pneumonia;
Lopinave/Litonawe;
Emtricitabine and tenofovir alafenamide fumarate;
Survival rate;
Length of hospital stay
- From:
Chinese Journal of Emergency Medicine
2020;29(3):E006-E006
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of a combination regimen by Lopinave/Litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for the treatment of novel coronavirus pneumonia (NCP).
Methods:We design the protocol as a real world study, which includes two groups: prospective intervention cohort (T1) and historical control group (T2). For T1 group, ninety patients will be enrolled who are diagnosed as NCP. All patients in T1 group will receive standard therapies following the recommendation in the guidelines of National Commission of Health, and they will be administered an anti-virus regimen includes LPV/r and FTC/TAF. The T2 group will enroll patients who have received single regimen includes LPV/r. The major outcome is the survival rate of patients. Secondary outcomes are the time of seroconversion of RNA, ARDS progression rate and length of hospital stay.
Conclusions:The results of this real world study might provide clinical practitioners a high efficiency and fast antivirus regimen for NCP. In addition, the conduction of this study will accelerate screening for other new effective therapeutic method.
